A. Sumberaz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
A. Sumberaz has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Gianni Testino
Unit of Addiction and Hepatology/Alcohological Regional Center, ASL3 Liguria, San Martino Polyclinic Hospital, Genoa, Italy -
15 shared publications - Paolo Borro
Department of Specialistic Medicine, S. Martino Hospital, Genoa, Italy
11 shared publications E. Andorno
4 shared publicationsF. Ansaldi
4 shared publications- Gianni Testino
Unit of Hepato-Gastroenterology, S. Martino Hospital, Genova, Italy
4 shared publications O.A. Ancarani
4 shared publications
Latest Publications
- 1 March 2014
- Published by Elsevier in Digestive and Liver Disease
- Vol. 46, S122
P.17.6 ALCOHOLISM AND TREATMENT OF HEPATITIS C VIRUS
- 1 March 2014
- Published by Elsevier in Digestive and Liver Disease
- Vol. 46, S122
P.17.6 ALCOHOLISM AND TREATMENT OF HEPATITIS C VIRUS
- 1 April 2013
- Vol. 104 (2) , 225-32
Recurrent hepatitis C and non-alcoholic fatty liver disease in transplanted patients: a review.
Non-alcoholic fatty liver disease (NAFLD) is a common occurrence after orthotopic liver transplantation (OLT). The association steatosis/HCV determines important implications for clinical practice: steatosis accelerates the progression of fibrosis and reduces the likelihood of obtaining a sustained virological response (SVR) with antiviral therapy. In post-transplant HCV patients we have evidenced a strong correlation between body mass index (BMI), cholesterol, triglycerides (TGC) and hepatic percentage of steatosis. In subjects with BMI <25 and TGC <160 ng/mL, the chance of SVR was 48 times higher than that of non response. The chances of SVR and sustained biochemical response for patients with percentage of steatosis <15 were 12 times higher than that with higher percentage of steatosis. We can conclude how the amount of steatosis be noted specifically in biopsy examination reports of patients with relapse chronic hepatitis C and how the management of dismetabolism, diet and exercise therapy can improve BMI, liver histology and the response to antiviral therapy.
- 1 April 2013
- Vol. 104 (2) , 225-32
Recurrent hepatitis C and non-alcoholic fatty liver disease in transplanted patients: a review.
Non-alcoholic fatty liver disease (NAFLD) is a common occurrence after orthotopic liver transplantation (OLT). The association steatosis/HCV determines important implications for clinical practice: steatosis accelerates the progression of fibrosis and reduces the likelihood of obtaining a sustained virological response (SVR) with antiviral therapy. In post-transplant HCV patients we have evidenced a strong correlation between body mass index (BMI), cholesterol, triglycerides (TGC) and hepatic percentage of steatosis. In subjects with BMI <25 and TGC <160 ng/mL, the chance of SVR was 48 times higher than that of non response. The chances of SVR and sustained biochemical response for patients with percentage of steatosis <15 were 12 times higher than that with higher percentage of steatosis. We can conclude how the amount of steatosis be noted specifically in biopsy examination reports of patients with relapse chronic hepatitis C and how the management of dismetabolism, diet and exercise therapy can improve BMI, liver histology and the response to antiviral therapy.
- 1 April 2012
- Vol. 16 (4) , 512-8
Human carcinogenesis and alcohol in hepato-gastroenterology.
Alcohol consumption is one of the top-10 risks for worldwide burden of disease. The International Agency for Research for Cancer affirmed that there was evidence for the carcinogenicity of ethanol in animals and classified alcohol consumption as carcinogenic for humans. Alcohol consumption causes cancers of the oral cavity, pharynx, larynx, oesophagus, colorectum, liver, pancreas and female breast. Most alcohol-induced diseases increases in a linear fashion as intake increases: oral, oesophagus and colon cancer fall into this pattern: very little is known about safe margins of alcohol consumption. Given the linear dose-response relation between alcohol intake and risk of cancer, control of heavy drinking remains the main target for cancer control. European Code Against Cancer recommends keeping daily consumption within two drinks (20 g [corrected] of alcohol/day) for man and one drink for women and US Department of Health and Human Services suggest as a low risk, a maximum of 10 g [corrected] of alcohol a day in man and half of this in women.
- 1 April 2012
- Vol. 16 (4) , 512-8
Human carcinogenesis and alcohol in hepato-gastroenterology.
Alcohol consumption is one of the top-10 risks for worldwide burden of disease. The International Agency for Research for Cancer affirmed that there was evidence for the carcinogenicity of ethanol in animals and classified alcohol consumption as carcinogenic for humans. Alcohol consumption causes cancers of the oral cavity, pharynx, larynx, oesophagus, colorectum, liver, pancreas and female breast. Most alcohol-induced diseases increases in a linear fashion as intake increases: oral, oesophagus and colon cancer fall into this pattern: very little is known about safe margins of alcohol consumption. Given the linear dose-response relation between alcohol intake and risk of cancer, control of heavy drinking remains the main target for cancer control. European Code Against Cancer recommends keeping daily consumption within two drinks (20 g [corrected] of alcohol/day) for man and one drink for women and US Department of Health and Human Services suggest as a low risk, a maximum of 10 g [corrected] of alcohol a day in man and half of this in women.
- 31 March 2011
- Published by Elsevier in Digestive and Liver Disease
- Vol. 43, S253
P.1.316: COMET ASSAY IN PERIPHERAL BLOOD LYMPHOCYTES IN SUBJECTS WITH NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
- 31 March 2011
- Published by Elsevier in Digestive and Liver Disease
- Vol. 43, S253
P.1.316: COMET ASSAY IN PERIPHERAL BLOOD LYMPHOCYTES IN SUBJECTS WITH NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
- 31 March 2011
- Published by Elsevier in Digestive and Liver Disease
- Vol. 43, S250
P.1.308: ACUTE ALCOHOLIC HEPATITIS IN CIRRHOSIS PATIENTS WITH HEPATORENAL SYNDROME TYPE I: ROLE OF TRANSJUGULAR PORTO-SYSTEMIC STENT SHUNT
- 31 March 2011
- Published by Elsevier in Digestive and Liver Disease
- Vol. 43, S250
P.1.308: ACUTE ALCOHOLIC HEPATITIS IN CIRRHOSIS PATIENTS WITH HEPATORENAL SYNDROME TYPE I: ROLE OF TRANSJUGULAR PORTO-SYSTEMIC STENT SHUNT
- 31 March 2011
- Published by Elsevier in Digestive and Liver Disease
- Vol. 43, S246
P.1.294: HCV RECURRENCE AFTER LIVER TRANSPLANTATION: ROLE OF THERAPY WITH PEGINTERFERON ALFA-2A/RIBAVIRIN IN MAINTENANCE
- 31 March 2011
- Published by Elsevier in Digestive and Liver Disease
- Vol. 43, S246
P.1.294: HCV RECURRENCE AFTER LIVER TRANSPLANTATION: ROLE OF THERAPY WITH PEGINTERFERON ALFA-2A/RIBAVIRIN IN MAINTENANCE
- 1 June 2009
- Vol. 51 (2) , 135-6
Pegylated interferon alfa-2a and ribavirin treatment for recurrent hepatitis C: role of steatosis and body mass index.
- 1 June 2009
- Vol. 51 (2) , 135-6
Pegylated interferon alfa-2a and ribavirin treatment for recurrent hepatitis C: role of steatosis and body mass index.
- 31 March 2009
- Published by Elsevier in Digestive and Liver Disease
- Vol. 41, S107-S108
A NEW STATISTICAL MODEL TO PREDICT SEVERE FIBROSIS IN PATIENTS WITH LIVER DISEASES
- 31 March 2009
- Published by Elsevier in Digestive and Liver Disease
- Vol. 41, S107-S108
A NEW STATISTICAL MODEL TO PREDICT SEVERE FIBROSIS IN PATIENTS WITH LIVER DISEASES